Dermatology

Latest News

Scripius Removes Dupixent from Formulary
Scripius Removes Dupixent from Formulary

September 7th 2023

The decision by Scripius (previously Select Health Prescriptions) was made based on the cost of Dupixent, as well as because of an increased demand to use Dupixent for mild atopic dermatitis when the primary patient population is those with moderate to severe disease.

 FDA Approves First Drug for Skin Infection from Pox Virus
FDA Approves First Drug for Skin Infection from Pox Virus

July 24th 2023

FDA Approves Pfizer’s Alopecia Drug
FDA Approves Pfizer’s Alopecia Drug

June 26th 2023

NDA Sets Goal Date for Skin Infection Gel
NDA Sets Goal Date for Skin Infection Gel

March 7th 2023

FDA Expands Cibinqo Label for Atopic Dermatitis in Adolescents
FDA Expands Cibinqo Label for Atopic Dermatitis in Adolescents

February 11th 2023

More News

© 2023 MJH Life Sciences

All rights reserved.